AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22246615 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet + web‐based parent training sessions
Number of subjects: 99
Study 22145355 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% acid‐soluble chitosan solution (200‐250 kDa molecular weight)
Number of subjects: 76
Study 22145355 — intervention group
Group type: COMPARATOR
Intervention: Control group (practically healthy women)
Number of subjects: 76
Study 19628651 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of acylated ghrelin (AG) 100 microg and unacylated ghrelin (UAG) 100 microg (Comb)
Number of subjects: 8
Study 19628651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 19628651 — intervention group
Group type: COMPARATOR
Intervention: Unacylated ghrelin (UAG) 200 microg
Number of subjects: 8
Study 16358341 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal expiratory pressures (P(Emax))
Number of subjects: 24
Study 16358341 — intervention group
Group type: COMPARATOR
Intervention: Forced vital capacity (FVC)
Number of subjects: 24
Study 15546290 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-coated stents
Number of subjects: 42
Study 15546290 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (Control)
Number of subjects: 42
Study 27272073 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical agent designed to reduce P. acnes biofilm
Number of subjects: 0
Study 10822123 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (0.625 mg/day oral conjugated estrogen)
Number of subjects: 309
Study 10822123 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy with continuous low-dose progestin (2.5 mg oral medroxyprogesterone acetate/day)
Number of subjects: 309
Study 10822123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 8628357 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol plus isosorbide mononitrate
Number of subjects: 86
Study 8628357 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 86
Study 2010785 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsiveness index
Number of subjects: 0
Study 2010785 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different instruments
Number of subjects: 0
Study 6405431 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage (0.50 g/kg body weight)
Number of subjects: 48
Study 6405431 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 48
Study 30130407 — intervention group
Group type: EXPERIMENTAL
Intervention: AuNR@SiO2
Number of subjects: 4
Study 30130407 — intervention group
Group type: COMPARATOR
Intervention: AuNR@CTAB, AuNR@PSS, AuNR@mPEG
Number of subjects: 4
Study 27173369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (5 mg/kg)
Number of subjects: 159
Study 27173369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 24477761 — intervention group
Group type: EXPERIMENTAL
Intervention: Full DoF reaching movements
Number of subjects: 0
Study 24477761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangential hand velocity
Number of subjects: 0
Study 23155023 — intervention group
Group type: EXPERIMENTAL
Intervention: SBM-based diet with GGMO-AX (4%)
Number of subjects: 200
Study 23155023 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI-based diet with cellulose (4%)
Number of subjects: 200
Study 23155023 — intervention group
Group type: EXPERIMENTAL
Intervention: SBM-based diet
Number of subjects: 200
Study 23155023 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected chicks (SBM-fed)
Number of subjects: 200
Study 23155023 — intervention group
Group type: COMPARATOR
Intervention: Infection status
Number of subjects: 200
Study 23155023 — intervention group
Group type: COMPARATOR
Intervention: Cecal tonsil cytokine expression
Number of subjects: 200
Study 20236248 — intervention group
Group type: EXPERIMENTAL
Intervention: ADX10059 125 mg b.i.d.
Number of subjects: 24
Study 20236248 — intervention group
Group type: EXPERIMENTAL
Intervention: ADX10059 250 mg b.i.d.
Number of subjects: 24
Study 20236248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17261559 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (various protocols including drop squats, slow eccentric movement, squatting on decline board or level ground, etc.) for 12 weeks, twice daily.
Number of subjects: 162
Study 17261559 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training with decline board and some level of discomfort.
Number of subjects: 162
Study 15855570 — intervention group
Group type: EXPERIMENTAL
Intervention: INH (6 mg)
Number of subjects: 17
Study 11997197 — intervention group
Group type: EXPERIMENTAL
Intervention: Avinza 30 mg once daily
Number of subjects: 295
Study 11997197 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Contin 15 mg twice daily
Number of subjects: 295
Study 11997197 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 295
Study 9803694 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus vouchers for cocaine-free urine samples (Voucher Schedule 1)
Number of subjects: 90
Study 9803694 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher Schedule 2 (high initial voucher values, increasing requirements)
Number of subjects: 90
Study 9803694 — intervention group
Group type: COMPARATOR
Intervention: Voucher Schedule 1 (low initial voucher values, increasing requirements)
Number of subjects: 90
Study 14588450 — intervention group
Group type: EXPERIMENTAL
Intervention: Malingering group (n = 30)
Number of subjects: 60
Study 14588450 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 60
Study 2749302 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care educational session
Number of subjects: 572
Study 2749302 — intervention group
Group type: COMPARATOR
Intervention: No self-care educational session (Control)
Number of subjects: 572
Study 30107283 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI3902 (250 mg)
Number of subjects: 56
Study 30107283 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI3902 (750 mg)
Number of subjects: 56
Study 30107283 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI3902 (1500 mg)
Number of subjects: 56
Study 30107283 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI3902 (3000 mg)
Number of subjects: 56
Study 30107283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 29943364 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment (100 mg/day)
Number of subjects: 111
Study 29943364 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 111
Study 26763226 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete pulmonary vein isolation (PVI) (group B)
Number of subjects: 233
Study 26763226 — intervention group
Group type: COMPARATOR
Intervention: Incomplete pulmonary vein isolation (PVI) (group A)
Number of subjects: 233
Study 24587780 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon radiotherapy (70 Gy)
Number of subjects: 27
Study 22467247 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation (needle inserted at TE5 point, gentle tapping for 90 s)
Number of subjects: 55
Study 22467247 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 55
Study 19680082 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (SIM)
Number of subjects: 33
Study 19680082 — intervention group
Group type: COMPARATOR
Intervention: No simulation training (CON)
Number of subjects: 33
Study 17005222 — intervention group
Group type: EXPERIMENTAL
Intervention: Coartem
Number of subjects: 500
Study 17005222 — intervention group
Group type: COMPARATOR
Intervention: AQ+SP
Number of subjects: 500
Study 16194047 — intervention group
Group type: EXPERIMENTAL
Intervention: Liv-52 for 6 months
Number of subjects: 36
Study 16194047 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 36
Study 11906367 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine
Number of subjects: 12
Study 11906367 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine
Number of subjects: 12
Study 11906367 — intervention group
Group type: EXPERIMENTAL
Intervention: ebastine
Number of subjects: 12
Study 11906367 — intervention group
Group type: EXPERIMENTAL
Intervention: fexofenadine
Number of subjects: 12
Study 11906367 — intervention group
Group type: EXPERIMENTAL
Intervention: mizolastine
Number of subjects: 12
Study 11906367 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 10479835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram/kg remifentanil (Group A)
Number of subjects: 60
Study 10479835 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg remifentanil (Group B)
Number of subjects: 60
Study 10479835 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms/kg remifentanil (Group C)
Number of subjects: 60
Study 10479835 — intervention group
Group type: COMPARATOR
Intervention: Control (All groups)
Number of subjects: 60
Study 7710545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 260
Study 7710545 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 260
Study 1936422 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 350 (75.49% iohexol, 350 mgI ml‐1)
Number of subjects: 80
Study 1936422 — intervention group
Group type: COMPARATOR
Intervention: Angioconray (80% sodium iothalamate, 480 mgI ml‐1)
Number of subjects: 80
Study 1936422 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 350
Number of subjects: 80
Study 1936422 — intervention group
Group type: COMPARATOR
Intervention: Angioconray
Number of subjects: 80
Study 7147192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 26
Study 7147192 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study 31978438 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater Rochester LARC Initiative
Number of subjects: 100
Study 31978438 — intervention group
Group type: COMPARATOR
Intervention: New York State
Number of subjects: 100
Study 31978438 — intervention group
Group type: COMPARATOR
Intervention: New York City
Number of subjects: 100
Study 31978438 — intervention group
Group type: COMPARATOR
Intervention: United States overall
Number of subjects: 100
Study 30457920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 128
Study 30457920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 28585735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg green tea extract, two capsules/day
Number of subjects: 68
Study 28585735 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg starch, two capsules/day
Number of subjects: 68
Study 24993562 — intervention group
Group type: COMPARATOR
Intervention: SINGLE (once daily training)
Number of subjects: 20
Study 24993562 — intervention group
Group type: EXPERIMENTAL
Intervention: REPEATED (twice every second day training)
Number of subjects: 20
Study 23434504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU 4 times per day)
Number of subjects: 39
Study 23434504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 21372694 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (5/160 mg) in the morning
Number of subjects: 463
Study 21372694 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (5/160 mg) in the evening
Number of subjects: 463
Study 21372694 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (10/160 mg) after uptitration if needed
Number of subjects: 463
Study 21372694 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 463
Study 19109514 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic precachexia (class 1)
Number of subjects: 1307
Study 19109514 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic cachexia (class 4)
Number of subjects: 1307
Study 17970056 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 15380292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg)
Number of subjects: 10
Study 15380292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (8 mg)
Number of subjects: 10
Study 15380292 — intervention group
Group type: COMPARATOR
Intervention: Cocaine (150 mg)
Number of subjects: 10
Study 11340346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotic group
Number of subjects: 33
Study 9701103 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10-40 mg/d), possibly combined with enalapril maleate (5-20 mg/d) and/or hydrochlorothiazide (12.5-25 mg/d)
Number of subjects: 4695
Study 8149523 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma endothelin determination on day 3 after myocardial infarction
Number of subjects: 142
Study 8149523 — intervention group
Group type: COMPARATOR
Intervention: Clinical and biochemical variables (age, previous treatment for systemic hypertension, presence of clinical heart failure, plasma atrial natriuretic factor levels)
Number of subjects: 142
Study 3141641 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire change every 3 days
Number of subjects: 126
Study 3141641 — intervention group
Group type: COMPARATOR
Intervention: Guidewire changes for mechanical or septic complications only
Number of subjects: 126
Study 29622155 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure (HF)
Number of subjects: 28341
Study 29622155 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmark method analysis at 70 years of age
Number of subjects: 28341
Study 26427002 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class didactic teaching (group 1)
Number of subjects: 18
Study 26427002 — intervention group
Group type: COMPARATOR
Intervention: Self-directed teaching (group 2)
Number of subjects: 18
Study 26427002 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy
Number of subjects: 18
Study 25236478 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component physical activity intervention (PA during academic lessons, PA during recess, PA homework, cycling campaign) for 5 months.
Number of subjects: 759
Study 22099051 — intervention group
Group type: EXPERIMENTAL
Intervention: RHES plus radiotherapy
Number of subjects: 50
Study 22099051 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 50
Study 20649631 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI)
Number of subjects: 98
Study 20649631 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Intervention (EI)
Number of subjects: 98
Study 20649631 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 98
Study 20649631 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI) and Extended Intervention (EI)
Number of subjects: 98
Study 18793245 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20,000 or 40,000 IU per week)
Number of subjects: 441
Study 18793245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 16351387 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Abstinence Self-Efficacy (ASE)
Number of subjects: 305
Study 16351387 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Smoking Outcome Expectancies (POEs)
Number of subjects: 305
Study 12009390 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 12
Study 12009390 — intervention group
Group type: COMPARATOR
Intervention: Minimal acupuncture (placebo)
Number of subjects: 12
Study 10736883 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (invitation to consult with a trained practice nurse)
Number of subjects: 270
Study 10736883 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 270
Study 10736883 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 270
Study 7601995 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based education/support programme
Number of subjects: 0
Study 2190851 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa (1.5 g daily)
Number of subjects: 40
Study 2190851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dummy tablet)
Number of subjects: 40
Study 7438324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystectomy plus preoperative irradiation (6.5 Gy X 2F/1 week) with misonidazole (3 g/m2, two doses, orally)
Number of subjects: 28
Study 7438324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystectomy plus preoperative irradiation (4.0 Gy X 5F) with misonidazole (2 g/m2)
Number of subjects: 28
Study 7438324 — intervention group
Group type: EXPERIMENTAL
Intervention: Split course (SC) protracted regime with misonidazole (0.5 g/m2 daily doses, total dose 14 g/m2 over 61 days)
Number of subjects: 28
Study 7438324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HF) with misonidazole (2 g/m2 daily doses, total dose 14 g/m2 over 35 days)
Number of subjects: 28
Study 7438324 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy alone
Number of subjects: 28
Study 7438324 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy plus preoperative irradiation (6.5 Gy X 2F/1 week) without misonidazole
Number of subjects: 28
Study 7438324 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy plus preoperative irradiation (4.0 Gy X 5F) without misonidazole
Number of subjects: 28
Study 31251892 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-guided aerobic training (n=11; 16 weeks, 20 min, twice weekly at RPE 3-6)
Number of subjects: 19
Study 31251892 — intervention group
Group type: COMPARATOR
Intervention: Active control (n=8; access to exercise equipment without specific advice)
Number of subjects: 19
Study 31152658 — intervention group
Group type: EXPERIMENTAL
Intervention: mMPC (mineral modified milk protein concentrate)
Number of subjects: 30
Study 31152658 — intervention group
Group type: COMPARATOR
Intervention: MPC (milk protein concentrate)
Number of subjects: 30
Study 31152658 — intervention group
Group type: COMPARATOR
Intervention: CAS (calcium caseinate)
Number of subjects: 30
Study 31152658 — intervention group
Group type: EXPERIMENTAL
Intervention: mMPC
Number of subjects: 30
Study 31152658 — intervention group
Group type: COMPARATOR
Intervention: All groups (mMPC, MPC, CAS)
Number of subjects: 30
Study 27577177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (POMx), 2 capsules of 250 mg per day for 8 weeks
Number of subjects: 55
Study 27577177 — intervention group
Group type: COMPARATOR
Intervention: Cellulose (control), 2 capsules of 250 mg per day for 8 weeks
Number of subjects: 55
Study 26176930 — intervention group
Group type: EXPERIMENTAL
Intervention: active tDCS
Number of subjects: 240
Study 26176930 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS/escitalopram 20 mg/day
Number of subjects: 240
Study 26176930 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS/placebo pill
Number of subjects: 240
Study 22717170 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐tryptophan (2.8g/d)
Number of subjects: 46
Study 22717170 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 22358274 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation) applied for 30 minutes, three times a day, along with analgesic therapy and physiotherapy.
Number of subjects: 20
Study 22358274 — intervention group
Group type: COMPARATOR
Intervention: Control group received more physiotherapy analgesic therapy without TENS.
Number of subjects: 20
Study 22358274 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS group for inspiratory muscle strength.
Number of subjects: 20
Study 22358274 — intervention group
Group type: COMPARATOR
Intervention: Control group for inspiratory muscle strength.
Number of subjects: 20
Study 22358274 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS group for expiratory muscle strength.
Number of subjects: 20
Study 22358274 — intervention group
Group type: COMPARATOR
Intervention: Control group for expiratory muscle strength.
Number of subjects: 20
Study 18327706 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant-based regimen (day 1: aprepitant 125 mg, ondansetron 8 mg, dexamethasone 12 mg before chemotherapy; ondansetron 8 mg 8 h later; days 2-3: aprepitant 80 mg qd)
Number of subjects: 124
Study 18327706 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (day 1: ondansetron 8 mg and dexamethasone 20 mg before chemotherapy; ondansetron 8 mg 8 h later; days 2-3: ondansetron 8 mg bid)
Number of subjects: 124
Study 18327706 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant-based regimen
Number of subjects: 124
Study 17347792 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length autologous slings (Group A)
Number of subjects: 165
Study 17347792 — intervention group
Group type: COMPARATOR
Intervention: Modified 'sling-on-a-string' technique (Group B)
Number of subjects: 165
Study 15033400 — intervention group
Group type: EXPERIMENTAL
Intervention: Yasmin (30 microg ethinylestradiol + 3 mg drospirenone)
Number of subjects: 50
Study 15033400 — intervention group
Group type: COMPARATOR
Intervention: Marvelon (30 microg ethinylestradiol + 150 microg desogestrel)
Number of subjects: 50
Study 11793859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA) at an initial dosage of 5 mg.kg‐1.d‐1, gradually tailed off over three months and maintained at 2 mg.kg‐1.d‐1 for 12 months.
Number of subjects: 30
Study 11793859 — intervention group
Group type: COMPARATOR
Intervention: Captopril (CAP) at a dosage of 37.5 mg/day.
Number of subjects: 30
Study 9547527 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Find screening and assessment (CF group)
Number of subjects: 128
Study 9547527 — intervention group
Group type: COMPARATOR
Intervention: Nonreferred children (Comparison group)
Number of subjects: 128
Study 8063043 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of the ACTH4-9 analogue ORG 2766 every 24 h
Number of subjects: 62
Study 8063043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3281838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium meglumine ioxaglate (320 or 306 mg I/ml)
Number of subjects: 209
Study 3281838 — intervention group
Group type: COMPARATOR
Intervention: Meglumine diatrizoate (306 mg I/ml)
Number of subjects: 209